

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057233 A1

(51) International Patent Classification⁷: C07D 211/26,
A61K 31/4465, C07D 211/58, 207/12, 207/14, 295/125,
241/04, C07C 275/28, A61P 3/04

(21) International Application Number: PCT/US01/45242

(22) International Filing Date:
29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/250,502 1 December 2000 (01.12.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV,
MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT,
RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ,
VN, YU, ZA.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(71) Applicant: SCHERING CORPORATION [US/US];
Patent Department - K-6-1 1990, 2000 Galloping Hill
Road, Kenilworth, NJ 07033-0530 (US).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

(72) Inventors: MC BRIAR, Mark, D.; 1155 Monroe Drive,
Stewartville, NJ 08886 (US). PALANI, Anandan; 25
Reinhart Way, Bridgewater, NJ 08807 (US). SHAPIRO,
Sherry, A.; 574 East Road, Belford, NJ 07718 (US).
XU, Ruo; 66 Dogwood Lane, Watchung, NJ 07060 (US).
CLADER, John; 428 North Union Avenue, Cranford, NJ
07016 (US).


Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
— entirely in electronic form (except for this front page) and
available upon request from the International Bureau

(74) Agent: KORSEN, Elliott; Schering-Plough Corporation,
Patent Department - K-6-1 1990, 2000 Galloping Hill
Road, Kenilworth, NJ 07033-0530 (US).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY



(I)

(57) Abstract: The present invention related to compounds of the formula
(I) or a pharmaceutically acceptable addition salt and/or hydrate thereof;
where applicable, a geometric or optical isomer or racemic mixture thereof;
which are useful for the treatment of metabolic and eating disorders, such
as hyperphagia, and for the treatment of diabetes.

WO 02/057233 A1

BEST AVAILABLE COPY

MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY

5 BACKGROUND OF THE INVENTION


This invention relates to antagonists of melanin-concentrating hormone (MCH) and their use in the treatment of eating disorders, metabolic disorders and diabetes.

MCH, a cyclic peptide, was first identified over a decade ago in teleost fish where it appears to regulate color change. More recently, MCH has been the subject
10 of investigation for its possible role as a regulator of eating behavior in mammals. As reported by Shimada et al., *Nature*, Vol. 396 (17 Dec. 1998), pp. 670-673, MCH-deficient mice have reduced body weight and leanness due to hypophagia (reduced feeding). In view of their findings, the authors have suggested that antagonists of MCH action may be effective for the treatment of obesity. U.S. Patent No. 5,908,830
15 discloses a combination therapy for the treatment of diabetes or obesity involving the administration of a metabolic rate increasing agent and a feeding behavior modifying agent, an example of the latter being an MCH antagonist. U.S. Patent No. 6,043,246 discloses urea derivatives said to be useful as neuropeptide Y receptor antagonists and as agents for the treatment of, *inter alia*, diseases of the metabolic system
20 including obesity and diabetes. Published PCT patent application WO 00/27845 describes a class of compounds, characterized therein as spiro-indolines, said to be selective neuropeptide Y Y5 antagonists and useful for the treatment of obesity and the complications associated therewith. Commonly assigned, copending U.S. patent application Serial No. 09/950,908 discloses and claims aryl-substituted urea
25 neuropeptide Y Y5 antagonists and their use in the treatment of obesity, hyperphagia (increased feeding) and diabetes.

SUMMARY OF THE INVENTION

The present invention relates to compounds of the general formula

- 2 -



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

5 wherein

Ar¹ is an aryl or heteroaryl group,

Ar² is an aryl, heteroaryl or aralkyl group or Ar¹ and Ar² together form a fluorene, substituted fluorene or fluorenone group with the proviso that Ar³ must be arylene;

10 Ar³ is an arylene or heteroarylene group;


said Ar¹, Ar² and Ar³ groups possessing 0 to 3 substituents independently selected from the group consisting of -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, halo, -CN, -(C₁-C₆)alkoxy, -CF₃, -OCF₃, -CONH₂, -CONH(C₁-C₆)alkyl, -CON(C₁-C₆)alkyl (C₁-C₆)alkyl, -NH₂, -NH C(O)(C₁-C₆)alkyl, -NHSO₂(C₁-C₆)alkyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -

15 SO₂(C₁-C₆)alkyl, methylenedioxy and NO₂;


X is O, S or N-CN;

Y is a single bond or a -(C₁-C₄)alkylene- group;


R¹ is thiazole, aryl or heteroaryl; or



20



- 3 -



5

R¹ is -N(R⁵)₂, -NHC(O)(C₂-C₃)alkylene N(R⁵)₂; -C(O)NH(C₂-C₃)alkylene N(R⁵)₂; C(O)N(Me)(C₂-C₃)alkyleneN(R⁵)₂, -C(OH)(C₁-C₂)alkyleneN(R⁵)₂, -N(Me)(C₂-C₃)alkyleneN(R⁵)₂, -NH(C₂-C₃)alkyleneC(O)R⁵, -N(Me)(C₂-C₃)alkyleneN(Me)SO₂(R⁵) or -N(Me)(C₂-C₃)alkyleneC(O)N(R⁵)₂;

10

R² is H or -(C₁-C₆)alkyl.

R³ is independently H, or nonsubstituted or halosubstituted
 -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₃-C₇)cycloalkyl(C₁-C₆)alkyl, -(C₁-C₆)alkoxy,
 15 -(C₁-C₆)alkoxy (C₁-C₆)alkylene, aryl, -aralkyl or -heteroaralkyl; or

- 4 -


R^4 is H, nonsubstituted or halosubstituted $-(C_1-C_6)alkyl$, $-NH(C_1-C_6)alkyl$, $-NHaryl$, aryl; or alkoxy or hydroxy substituted alkyl, and

R^5 is independently H, or nonsubstituted or halosubstituted $-(C_1-C_6)alkyl$, $-(C_3-C_7)cycloalkyl$, $-(C_3-C_7)cycloalkyl(C_1-C_6)alkyl$, aryl, $-aralkyl$, $-heteroaralkyl$, $-(C_1-C_6)alkoxy$ or $(C_1-C_6)alkylene(C_1-C_6)alkoxy$.

This invention also relates to compositions containing the compounds of the invention as well as methods of using the compounds for the treatment of metabolic disorders, eating disorders or diabetes. The compounds of the invention may be used along or in combination with other appropriate therapeutic agents.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds of the general formula



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar^1 is an aryl or heteroaryl group,

Ar^2 is an aryl, heteroaryl or aralkyl group or Ar^1 and Ar^2 together form a fluorene, substituted fluorene or fluorenone group with the proviso that Ar^3 must be arylene;

Ar^3 is an arylene or heteroarylene group;


said Ar^1 , Ar^2 and Ar^3 groups possessing 0 to 3 substituents independently selected from the group consisting of $-(C_1-C_6)alkyl$, $-(C_3-C_7)cycloalkyl$, halo, $-CN$, $-(C_1-C_6)alkoxy$, $-CF_3$, $-OCF_3$, $-CONH_2$, $-CONH(C_1-C_6)alkyl$, $-CON(C_1-C_6)alkyl$, $(C_1-C_6)alkyl$, $-NH_2$, $-NH C(O)(C_1-C_6)alkyl$, $-NHSO_2(C_1-C_6)alkyl$, $-S(C_1-C_6)alkyl$, $-SO(C_1-C_6)alkyl$, $-SO_2(C_1-C_6)alkyl$, methylenedioxy and NO_2 ;

- 5 -


X is O, S or N-CN;

Y is a single bond or a $-(C_1-C_4)$ alkylene- group; R^1 is thiazole, aryl or heteroaryl; or


5



10



- 6 -



- R^1 is $-N(R^5)_2$, $-NHC(O)(C_2-C_3)\text{alkylene } N(R^5)_2$; $-C(O)NH(C_2-C_3)\text{alkylene } N(R^5)_2$; $C(O)N(Me)(C_2-C_3)\text{alkylene } N(R^5)_2$, $-C(OH)(C_1-C_2)\text{alkylene } N(R^5)_2$, $-N(Me)(C_2-C_3)\text{alkylene } N(R^5)_2$, $-NH(C_2-C_3)\text{alkylene } C(O)R^5$, $-N(Me)(C_2-C_3)\text{alkylene } N(Me)SO_2(R^5)$ or $-N(Me)(C_2-C_3)\text{alkylene } C(O)N(R^5)_2$;

R^2 is H or $-(C_1-C_6)\text{alkyl}$.

- R^3 is independently H, or nonsubstituted or halosubstituted $-(C_1-C_6)\text{alkyl}$, $-(C_3-C_7)\text{cycloalkyl}$, $-(C_3-C_7)\text{cycloalkyl}(C_1-C_6)\text{alkyl}$, $-(C_1-C_6)\text{alkoxy}$, $-(C_1-C_6)\text{alkoxy } (C_1-C_6)\text{alkylene}$, aryl, -aralkyl or -heteroaralkyl; or

- R^4 is H, nonsubstituted or halosubstituted $-(C_1-C_6)\text{alkyl}$, $-NH(C_1-C_6)\text{alkyl}$, $-NH\text{aryl}$, aryl; or alkoxy or hydroxy substituted alkyl, and

- R^5 is independently H, or nonsubstituted or halosubstituted $-(C_1-C_6)\text{alkyl}$, $-(C_3-C_7)\text{cycloalkyl}$, $-(C_3-C_7)\text{cycloalkyl}(C_1-C_6)\text{alkyl}$, aryl, -aralkyl, -heteroaralkyl, $-(C_1-C_6)\text{alkoxy}$ or $(C_1-C_6)\text{alkylene}(C_1-C_6)\text{alkoxy}$.

20

This invention also relates to pharmaceutical compositions which comprise an amount of a compound of the invention, a pro-drug thereof, or a pharmaceutically

- 7 -

acceptable salt of said compound or of said pro-drug and a pharmaceutically acceptable carrier therefor.

The invention also relates to a method of treating a patient having a disease or condition mediated by MCH by administering a therapeutically effective amount of a
5 compound of the invention, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug to the mammal.

Further, this invention relates to a method of treating obesity comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the invention or a pro-drug thereof, or a pharmaceutically
10 acceptable salt of said compound or of said pro-drug.

Another aspect of this invention relates to a method for treating metabolic disorders such as obesity and eating disorders such as bulimia and anorexia comprising administering to a mammal a therapeutically effective amount of a compound of the invention, a pro-drug thereof, or a pharmaceutically acceptable salt
15 of said compound or of said pro-drug.

Another aspect of this invention relates to a method for treating hyperlipidemia comprising administering to a mammal a therapeutically effective amount of a compound of the invention, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug.

20 Another aspect of this invention is directed to a method for treating cellulite and fat accumulation comprising administering to a mammal a therapeutically effective amount of a compound of the invention, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug.

Another aspect of this invention is directed to a method for treating type II
25 diabetes comprising administering to a mammal a therapeutically effective amount of a compound of the invention, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug.

In addition to the "direct" effect of the compounds of this invention on the MCH subtype, there are diseases and conditions that will benefit from the weight loss such
30 as insulin resistance, impaired glucose tolerance, Type II Diabetes, hypertension, hyperlipidemia, cardiovascular disease, gall stones, certain cancers, and sleep apnea.

This invention is also directed to pharmaceutical compositions for the treatment of obesity which comprise an obesity treating amount of a compound of the invention,

- 8 -

a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug and a pharmaceutically acceptable carrier therefor.

In addition to monotherapies including the compounds of the invention, another aspect of this invention is combinations (such as, for example, dual combination
5 therapy, three combination therapy and the like,) of therapeutically effective amounts of a compound of the invention, or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or a pharmaceutically acceptable salt of said prodrug, and therapeutically effective amounts of one or more antiobesity/anorectic agent such as, for example, a β_3 agonist, a thyromimetic agent, or an NPY antagonist.

10 Still another aspect of this invention is a method for treating obesity comprising administering to a mammal (which term includes humans) in need of such treatment:

a. therapeutically effective amounts of a first compound, said first compound being a compound of the invention, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or a pharmaceutically acceptable
15 salt of said prodrug; and

b. therapeutically effective amounts of a second compound, said second compound being an antiobesity and/or anorectic agent such as, for example, a β_3 agonist, a thyromimetic agent, or an NPY antagonist, wherein the amounts of the first and second compounds result in the desired therapeutic effect of treating obesity.

20 This invention is also directed to a pharmaceutical composition comprising a combination of therapeutically effective amounts of a first compound, said first compound being a compound of the invention, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or a pharmaceutically acceptable salt of said prodrug; and therapeutically effective amounts of a second compound,
25 said second compound being an antiobesity and/or anorectic agent such as, for example, a β_3 agonist, a thyromimetic agent, or an NPY antagonist; and/or optionally a pharmaceutical acceptable carrier, vehicle or diluent.

Another aspect of this invention is a kit comprising:

a. therapeutically effective amounts of a first compound, said first
30 compound being a compound of the invention, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or a pharmaceutically acceptable salt of said prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

- 9 -

b. therapeutically effective amounts of a second compound, said second compound being an antiobesity and/or anorectic agent such as, for example, a β_3 agonist, a thyromimetic agent, or an NPY antagonist; and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

5 c. means for containing said first unit dosage form and said second unit dosage form, wherein the amounts of the first compound and of the second compound result in the desired therapeutic effect of treating obesity.

Illustrative non-limiting examples of preferred antiobesity and/or anorectic agents in the above combination methods, combination compositions and combination
10 kits include: phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, a cholecystokinin-A (hereinafter referred to as CCK-A) agonist, a monoamine reuptake inhibitor (such as, for example, sibutramine), a sympathomimetic agent, a serotonergic agent (such as, for example, dexfenfluramine or fenfluramine), a dopamine agonist (such as, for example, bromocriptine), a melanocyte-stimulating
15 hormone receptor agonist or mimetic, a melanocyte-stimulating hormone analog, a cannabinoid receptor antagonist, a melanin concentrating hormone antagonist, the OB protein (hereinafter referred to as "leptin"), a leptin analog, a leptin receptor agonist, a galanin antagonist or a GI lipase inhibitor or decreaser (such as orlistat). Other anorectic agents include bombesin agonists, dehydroepiandrosterone or analogs
20 thereof, glucocorticoid receptor agonists and antagonists, orexin receptor antagonists, urocortin binding protein antagonists, agonists of the glucagon-like peptide-1 receptor such as, for example, Exendin and ciliary neurotrophic factors such as, for example, Axokine.

Another aspect of this invention is a method for treating diabetes comprising
25 administering to a mammal:

a. therapeutically effective amounts of a first compound, said first compound being a Formula I compound (or a Formula II compound or a Formula III compound), a prodrug thereof, or a pharmaceutically acceptable salt of said compound or a pharmaceutically acceptable salt of said prodrug; and

30 b. therapeutically effective amounts of a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations),

- 10 -

an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosaglitazone, pioglitazone or GW-1929, a sulfonylurea, glipazide, glyburide, or chlorpropamide wherein the amounts of the first and second compounds result in the therapeutic effect of treating diabetes.

5

Unless otherwise stated or indicated, the following definitions apply throughout the specification and claims. These definitions apply regardless of whether a term is used by itself or in combination with other terms. Hence the definition of "alkyl" applies to "alkyl" as well as to the "alkyl" portions of "alkoxy", etc.

10

"Alkyl" represents a straight or branched saturated hydrocarbon chain having the designated number of carbon atoms. Where the number of carbon atoms is not specified, 1 to 6 carbons are intended.

"Halo" represents fluoro, chloro, bromo or iodo.

"Aryl" refers to a monoaromatic ring or a bicyclic nonfused or fused ring system
15 possessing one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, and the like. The aryl group can be unsubstituted or substituted with one, two, or three substituents independently selected from lower alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxamide, mercapto, sulfhydryl, amino, alkylamino and dialkylamino.

20

The term "heteroaryl" and the heteroaryl portion of the term "-heteroaralkyl" independently refer to 5- to 10-membered single, bicyclic or fused ring systems having at least one heteroaryl ring possessing from 1 to 3 heteroatoms independently selected from the group consisting of -O-, -S-, -N-, and -N=. Individual heteroaryl rings can be unsubstituted or substituted with one, two or three substituents
25 independently selected from lower alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxamide, mercapto, sulfhydryl, amino, alkylamino, dialkylamino.

When a variable appears more than once in the structural formula, for example R^3 or R^5 , the identity of each variable appearing more than once may be independently selected from the definition for that variable.

30

N-oxides can form on a tertiary nitrogen present in an R substituent, or on =N- in a heteroaryl ring substituent and are included in the compounds of the invention.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product

- 11 -

which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

In addition, it is well known to those skilled in the art that many of the foregoing heterocyclic groups can exist in more than one tautomeric form. It is intended that all such tautomers be included within the scope of this invention.

For compounds of the invention having at least one asymmetrical carbon atom, all isomers, including diastereomers, enantiomers and rotational isomers are contemplated as being part of this invention. These individual enantiomers are commonly designated according to the optical rotation they effect by the symbols (+) and (-), (L) and (D), (l) and (d) or combinations thereof. These isomers may also be designated according to their absolute spatial configuration by (R) and (S), which stands for sinister and rectus, respectively.

The individual isomers can be prepared using conventional resolution procedures, e.g., treatment with an appropriate optically active acid, separating the diastereomers and then recovering the desired isomer. In addition, the individual optical isomers may be prepared by asymmetric synthesis.

Compounds of the invention can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for purposes of this invention.

The compounds of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility and other desirable pharmaceutical properties.

A compound of the invention may form pharmaceutically acceptable salts with organic and inorganic acids. The term "pharmaceutically acceptable salt" is intended to include all acceptable salts. Examples of acid salts are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, citric, malonic, salicylic, maleic, fumaric, succinic, ascorbic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. Depending on the particular functionality of the compound, pharmaceutically acceptable salts of the compounds of the invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia,

- 12 -


ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris (hydroxymethyl)aminomethane, and tetramethylammonium hydroxide. These salts may be prepared by standard
 5 procedures such as reacting a free acid with a suitable organic or inorganic base, or alternatively by reacting a free base with a suitable organic or inorganic acid.

Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed such as methyl, ethyl, butyl, acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for
 10 modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

In a preferred group of compounds of the invention,

Ar¹ and Ar² are independently phenyl or pyridyl,

15 Ar³ is 1, 4-arylene,



wherein R³ is -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkylmethyl, (C₁-C₆)alkoxy- or (C₁-C₆)alkoxy(C₁-C₆)alkylene-,

R² is H,

X is O; and

20 Y is a single bond or -(C₁-C₂)alkylene.

In another preferred group of compounds of the invention,

Ar¹ and Ar² are independently phenyl or pyridyl,

Ar³ is 1,4-arylene,

25 R¹ is -N(R⁵)₂ or -C(O)NH(C₂-C₃)alkylene N(R⁵)₂ in which each R⁵ is independently H, -(C₁-C₆)alkyl, -ar(C₁-C₆)alkyl, heteroaryl, heteroarylalkyl, halo-substituted -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl,

X is O; and



Y is -(C₂-C₃)alkylene.

30

In still another preferred group of compounds of the invention,

Ar¹ and Ar² are independently phenyl or pyridyl,

- 13 -

Ar³ is 1,4-arylene,R¹ is one of the groups

5

X is O; and

Y is -(C₂-C₃)alkylene.

- 10 In the above preferred groups, especially preferred compounds are those in which Ar¹ is 3-substituted phenyl, most preferably those in which the 3-substitution is -CN, -OCF₃ or chloro, or Ar¹ is pyridyl, Ar² is halo-substituted or CF₃-substituted phenyl or pyridyl and any of R³, R⁴ and R⁵, where present, is methyl, ethyl, propyl, -CH₂CH₂CF₃, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.

15

Preferred compounds of the invention include those shown in the following table:

	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N-[2-[1-(CYCLOPROPYLMETHYL)-4-PIPERIDINYL]ETHYL]-N'-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]UREA</p>	
--	--	--





- 14 -

	<p>N-[4'-[(1-CYCLOPENTYL-4-PIPERIDINYL)[[(3,5-DICHLOROPHENYL)AMINO]CARBONYL]AMINO][1,1'-BIPHENYL]-3-YL]ACETAMIDE</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]-N-[2-(3(R)-METHOXY-1-PYRROLIDINYL)ETHYL]UREA</p>	
	<p>N'-(3-CHLORO-4-FLUOROPHENYL)-N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N-(1-CYCLOPENTYL-4-PIPERIDINYL)UREA</p>	
	<p>N-[1-[2-[[3'-CYANO[1,1'-BIPHENYL]-4-YL][[(3,5-DICHLOROPHENYL)AMINO]CARBONYL]AMINO]ETHYL]-3(R)-PYRROLIDINYL]-N'-ETHYLUREA</p>	





- 15 -

	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]-N-[2-(4-METHYL-1-PIPERAZINYL)ETHYL]UREA</p>	
	<p>N-[1-[4-[[[(3-CHLORO-4-FLUOROPHENYL)AMINO]CARBONYL][3'-CYANO[1,1'-BIPHENYL]-4-YL]AMINO]BUTYL]-3(R)-PYRROLIDINYL]ACETAMIDE</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N-[2-(2(S),4-DIMETHYL-1-PIPERAZINYL)ETHYL]-N'-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]UREA</p>	
	<p>N-[2-[[[2-[[[3'-CYANO[1,1'-BIPHENYL]-4-YL][[(3,5-DICHLOROPHENYL)AMINO]CARBONYL]AMINO]ETHYL]METHYLAMINO]ETHYL]-N-METHYLMETHANESULFONAMIDE</p>	





- 16 -

	<p>N'-(3-CHLORO-4-FLUOROPHENYL)-N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N-[2-(DIMETHYLAMINO)ETHYL]UREA DIMETHYLAMINO)ETHYL]UREA</p>	
	<p>4-[[[(3-CHLORO-4-FLUOROPHENYL)AMINO]CARBONYL][3'-CYANO[1,1'-BIPHENYL]-4-YL]AMINO]-N-[2-(DIMETHYLAMINO)ETHYL]BUTANAMIDE</p>	
	<p>1-[[[2-[[3'-CYANO[1,1'-BIPHENYL]-4-YL][[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO]CARBONYL]AMINO]ETHYL]METHYLAMINO]ACETYL]PYRROLIDINE</p>	
	<p>3-[[2-[[3'-CYANO[1,1'-BIPHENYL]-4-YL][[3,4-DICHLOROPHENYL]AMINO]CARBONYL]AMINO]ETHYL]METHYLAMINO]-N,N-DIMETHYLPROPANAMIDE</p>	





- 17 -

	<p>N-[1-[2-[[3'-CYANO[1,1'-BIPHENYL]-4-YL]4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO]CARBONYL]AMINO]ETHYL]-3(R)-PIPERIDINYL]ETHANESULFONAMIDE</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[3-FLUORO-4-(TRIFLUOROMETHYL)PHENYL]-N-[2-(DIMETHYLAMINO)ETHYL]UREA</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]-N-[2-[2(S)-(HYDROXYMETHYL)-1-PYRROLIDINYL]ETHYL]UREA</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[(3,5-DICHLOROPHENYL)-N-[2-(PROPYLAMINO)ETHYL]UREA</p>	



	<p>N'-(3-CHLORO-4-FLUOROPHENYL)-N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N-[2-(CYCLOBUTYLAMINO)ETHYL]UREA</p>	
	<p>ETHYL [1-[2-[[3'-CYANO[1,1'-BIPHENYL]-4-YL]AMINO]CARBONYL]AMINO]ETHYL]-3(R)-PYRROLIDINYL]CARBAMATE</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-(5,6-DICHLORO-3-PYRIDINYL)-N-[2-(3(R)-HYDROXY-1-PYRROLIDINYL)ETHYL]UREA</p>	
	<p>N'-(4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL)-N-[2-(PROPYLAMINO)ETHYL]-N-[3'-(TRIFLUOROMETHOXY)[1,1'-BIPHENYL]-4-YL]UREA</p>	

	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[4-FLUORO-3-(TRIFLUOROMETHYL)PHENYL]-N-(2-PYRIDINYLMETHYL)UREA</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-[3-FLUORO-4-(TRIFLUOROMETHYL)PHENYL]-N-[2-(3(R)-HYDROXY-1-PYRROLIDINYL)ETHYL]UREA</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-(3,5-DICHLOROPHENYL)-N-[2-[2-OXO[1,3'(R)-BIPYRROLIDIN]-1'-YL]ETHYL]UREA</p>	
	<p>N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-(3,5-DICHLOROPHENYL)-N-[2-[3(R)-DIMETHYLAMINO]-1-PYRROLIDINYL]ETHYL]UREA</p>	

- 20 -

	N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N'-(3,5-DICHLOROPHENYL)-N-[(1-METHYL-2(R)-PYRROLIDINYL)METHYL]UREA	
	N-[3'-CYANO[1,1'-BIPHENYL]-4-YL]-N-[2-(CYCLOBUTYLAMINO)ETHYL]-N'-(3,5-DICHLOROPHENYL)UREA	
	N-(1-CYCLOPENTYL-4-PIPERIDINYL)-N'-(3,5-DICHLOROPHENYL)-N-[4-(3-PYRIDINYL)PHENYL]UREA	
	N'-(3-CHLORO-4-FLUOROPHENYL)-N-[4-(5-CYANO-3-PYRIDINYL)PHENYL]-N-[2-(DIMETHYLAMINO)ETHYL]UREA	

- 21 -

	N'-(3-CHLORO-4-FLUOROPHENYL)-N-(9H-FLUOREN-2-YL)-N-[2-(PROPYLAMINO)ETHYL]UREA	
	N-[6-(3-CYANOPHENYL)-3-PYRIDINYL]-N-(1-CYCLOPENTYL-4-PIPERIDINYL)-N'-(3,5-DICHLOROPHENYL)UREA	

Compounds of the invention can be produced by processes known to those skilled in the art and as shown in the following reaction schemes and in the preparations and examples below.


Preparations:

Biaryl ureas of type 1a are prepared via Method 1 as shown in Scheme 1a and Scheme 1b.

- 22 -


Method 1

Scheme 1a:



5

Scheme 1b:



10


Reductive alkylation of bromoaniline 2 with an aldehyde or ketone corresponding to group R^1 (as exemplified by n-BOC piperidone, $m=1$) affords amine 3 (Scheme 1a). Suzuki coupling of amine 3 with an aryl boronic acid gives biaryl amine 4. The BOC deprotection of biaryl amine of 4 is carried out using trifluoroacetic acid (Scheme 1b) and the resulting amine is reacted with a ketone or aldehyde under reductive alkylation conditions or with alkyl bromide to introduce group R^3 . Treatment of the resulting amine with isocyanate Ar^2NCO affords biaryl urea 1a.

Alternatively, the sequence of steps in scheme 1a can be reversed so that the reductive alkylation step is carried out after Suzuki coupling. The sequence of steps in scheme 1b can be reversed so that the urea formation is carried out before the deprotection with TFA.

20

Preparation of biaryl open chain ureas:


Biaryl ureas of type 1b are prepared via Methods 2 to 6.

Method 2:

- 5 Alkylation of bromide 5 in which k is 1 or 2 with 4-bromoaniline in the presence of a base such as Na_2CO_3 affords the diamine 6. Selective protection of the primary amine group with BOC_2O followed by Suzuki coupling with an aryl boronic acid provides biarylamine 7. Treatment of biarylamine 7 with isocyanate Ar^2NCO provides the urea functionality. Deprotection of BOC with TFA affords compounds 1b where R^1
- 10 is $-\text{NH}_2$. Reductive alkylation under standard conditions with R^1H gives with R^1H biaryl urea 1b wherein R^1 can be $-\text{NHR}^5$ or $-\text{N}(\text{R}^5)_2$ in which R^5 is $-(\text{C}_1-\text{C}_6)\text{alkyl}$, $-(\text{C}_3-\text{C}_7)\text{cycloalkyl}$ or $-(\text{C}_3-\text{C}_7)\text{cycloalkyl}(\text{C}_1-\text{C}_6)\text{alkyl}$.

Method 3:

15




- 24 -

Suzuki coupling between 4-bromoaniline and an aryl boronic acid affords the biaryl amine 9. Reductive alkylation of 9 with chloroaldehyde 10 under standard conditions gives chloride 11 in which k is 1 or 2. Nucleophilic displacement of chloride 11 with the appropriate amine followed by treatment with isocyanate Ar^2NCO affords the desired urea 1b in which R^1 is $-\text{N}(\text{R}^5)_2$, where R^5 is as previously defined or where $\text{N}(\text{R}^5)_2$ forms a cyclic amine as previously defined for R^1 .

Ureas 1b wherein R^1 contains a BOC protected amine group can be further modified by TFA deprotection of BOC followed by alkylation, reductive alkylation, acylation, sulfonylation, carbamate formation, urea formation, thiourea formation or sulfamide formation to form other R^1 groups as defined previously.

Ureas 1b wherein R^1 contains a ketal group can be further modified by HCl hydrolysis to the ketone followed by addition of Grignard reagent, oxime formation or reduction to alcohol to form other R^1 groups as defined previously.


15

Method 4:


Suzuki coupling between 4-bromoaniline and an aryl boronic acid affords biaryl amine 9. Nucleophilic displacement of 3-chloro-iodopropane affords the chloride 11. Nucleophilic displacement of chloride 11 with the appropriate amine followed by treatment with isocyanate Ar^2NCO affords the desired urea 1b in which $k = 2$ and R^1 is $-\text{N}(\text{R}^5)_2$ as defined in Method 3.

20

- 25 -

Method 5:

- Suzuki coupling between 4-bromoaniline and an aryl boronic acid affords biaryl
- 5 amine 9. Reductive alkylation or nucleophilic displacement of iodine gives chloride
11. Nucleophilic displacement of chloride 11 with the appropriate amine affords the
- secondary amine 13. Selective protection of the right-hand side alkyl amine group
- with BOC₂O gives intermediate 14. Treatment with isocyanate Ar²NCO followed by
- deprotection of BOC with trifluoroacetic acid affords 1b in which k is 1 or 2 and R¹ is –
- 10 NHR⁵ as defined in Method 2.


Method 6:

- Suzuki coupling between 4-bromoaniline and an aryl boronic acid affords biaryl
- 15 amine 9. Reductive alkylation with 2-hydroxy-tetrahydrofuran under standard
- conditions gives alcohol 15. Protection of the amine group with BOC₂O gives
- intermediate 16, followed by bromination gives bromide 17. Nucleophilic
- displacement of bromide 17 with the appropriate amine affords amine 18. The

- 26 -

deprotection of BOC is carried out with trifluoroacetic acid followed by treatment with isocyanate Ar^2NCO affords 1b in which k is 3 and R^1 is $-\text{N}(\text{R}^5)_2$ as defined in Method 3.

5 Biaryl ureas of type 1c are prepared via Method 7.



10 Suzuki coupling between 4-bromoaniline and an aryl boronic acid affords biaryl amine 9. Nucleophilic displacement of bromine gives ester 19 in which n is 1, 2 or 3. Treatment with isocyanate Ar^2NCO affords urea 20. Hydrolysis of the ester with either trifluoroacetic acid or NaOH affords carboxylic acid 21. Coupling of the acid with the appropriate amine affords 1c in which n is 1, 2 or 3 and R^1 is $-\text{NHR}^5$ as defined in Method 2 or $-\text{N}(\text{R}^5)_2$ as defined in Method 3.


15

Biaryl ureas of type 1d are prepared via Method 8.

Method 8:

20

- 27 -



Suzuki coupling between 4-bromoaniline and an aryl boronic acid affords biaryl amine 9. Reductive alkylation of 9 with proline under standard conditions followed by treatment with isocyanate Ar^2NCO affords urea 23. The BOC deprotection is carried out with trifluoroacetic acid and the resulting amine is reacted with ketone or aldehyde under reductive alkylation conditions or with alkyl bromide to introduce group R^3 , in which R^3 is as previously defined.

The compounds of the present invention exhibit MCH receptor antagonizing activity, which has been correlated with pharmaceutical activity for treating eating disorders, metabolic disorders and for the treatment of diabetes.

The compounds of the invention display pharmacological activity in the following assay designed to demonstrate MCH receptor antagonist activity. The compounds are non-toxic at pharmaceutically therapeutic doses.

MCH receptor binding assay

Membranes from CHO cells expressing the MCH receptor were prepared by lysing cells with 5 mM HEPES for 15 min at 4°C . Cell lysates were centrifuged ($12.5000 \times g$, 15 min) and the pellet was resuspended in 5 mM HEPES. For each 96-well plate (Microlite, Dynex Technologies), 1 mg of cell membranes were incubated with 10 mg of wheat germ agglutinin SPA beads (Amersham) for 5 min at 4°C in a volume of 10 ml of binding buffer (25 mM HEPES, 10 mM MgCl_2 , 10 mM NaCl, 5 mM MnCl_2 , 0.1% BSA). The membrane/bead mixture was centrifuged ($1500 \times g$, 3.5 min), the supernatant was aspirated, and the pellet was resuspended in 10 ml binding buffer. The centrifugation, aspiration and resuspension were then repeated. The membrane/bead mixture (100 μl) was then added to 96-well plates containing 50 μl of

- 28 -

500 pM [¹²⁵I]-MCH (NEN) and 50 ml of the appropriate concentration of compound (4X the desired final concentration). Nonspecific binding was determined by including 1 μM MCH in the binding reaction. The binding reaction was incubated at room temperature for 2 h. Plates were then analyzed in a TOPCOUNT microplate
5 scintillation counter (Packard). Data was analyzed and K_i values were determined using GraphPad Prim.

For the compounds of this invention, a range of MCH receptor binding activity (K_i values) of from about 0.5 nM to about 100 nM was observed. Compounds of this invention preferably have a binding activity in the range of from about 0.5 nM to about
10 50 nM, and more preferably from about 0.5 to about 10 nM.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or
15 syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.

20 Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for
25 example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

30 They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredients is mixed with an inert solid diluent, for example, calcium

- 29 -

carbonate, calcium phosphate or kaolin, or a soft gelatin capsules where in the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, e.g., sweetening, flavoring and coloring agents, may also be present.

- 30 -

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, e.g., olive oil or arachis oil, or a mineral oil, e.g., liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, e.g., soy beans, lecithin, and esters
5 or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, e.g., polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example,
10 glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending
15 agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, e.g., as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally
20 employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. The compositions can be prepared
25 by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of the invention are employed. (For purposes of this
30 application, topical application shall include mouthwashes and gargles.)

The compounds for the present invention can be administered in the intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.

- 31 -

To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin,
5 hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, weight, sex and medical condition of the patient; the severity of the condition to be treated; the
10 route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter, arrest or reverse the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a
15 regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. Preferably, doses of the compound of structural The invention useful in the method of the present invention range from 0.01 to 1000 mg per adult human per day. Most preferably, dosages range from 0.1 to 500 mg/day. For oral administration, the compositions are
20 preferably provided in the form of tablets containing 0.01 to 1000 milligrams of the active ingredient, particularly 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0002 mg/kg to about 50 mg/kg of body
25 weight per day. The range is more particularly from about 0.001 mg/kg to 1 mg/kg of body weight per day.

Advantageously, the active agent of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in dividend doses of two, three or four time daily.


30 The amount of active ingredient that may be combined with the carrier materials to produce single dosage form will vary depending upon the host treated and the particular mode of administration.

- 32 -

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route or administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

- 5 The following examples illustrate the preparation of some of the compounds of the invention and are not to be construed as limiting the invention disclosed herein.

EXAMPLE 1



10

N-(3'-cyano[1,1'-biphenyl]-4-yl)-N-(1-cyclopentyl-4-piperidiny)-N'-(,5-dichlorophenyl)urea

To a stirred solution of 4-bromoaniline (10.0 g, 58.13 mmol) and N-Boc-
15 piperidone (11.6 g, 58.13 mmol) was added titanium isopropoxide (20.78 mL, 69.72 mmol) and stirred at rt for 24 h. The reaction mixture was then cooled to 0°C and sodium cyanoborohydride (10.95 g, 174.3 mmol) was added in methanol (30 mL) drop-wise. The reaction was then stirred at 0°C for 20 mins and at rt for 5 h. The reaction mixture was then diluted with EtOAc:water (3:1), filtered through Celite. The
20 resulting filtrate was then washed over brine, dried over Na₂SO₄, concentrated and chromatographed over silica gel (eluting EtOAc/hexanes) to yield 20.9 g (49%) of amine as a solid.

To a stirred solution of amine (2.55 g, 7.18 mmol) in 30 mL of DME:H₂O (4:1) was added 3-cyanophenylboronic acid (2.11g, 14.4 mmol), PdCl₂(PPh₃)₂ (0.500g,
25 0.718 mmol), Na₂CO₃ (2.28 g, 21.55 mmol) and heated to 80°C for 24 h. The reaction mixture was then cooled to rt, poured into aqueous NaOH and extracted with ether. The combined extracts were then dried, concentrated and chromatographed to yield 1.46 g (54%) of biaryl amine as a solid.

To a stirred solution of biaryl amine (0.546 g, 1.45 mmol) in methylene chloride
30 (3 mL) was added trifluoroacetic acid (2.2 mL) and stirred at rt for 2 h. The reaction

- 33 -

mixture was then concentrated and poured into 10% NaOH and extracted with methylene chloride. The combined extracts were dried and concentrated to afford 0.357 g (89%) of amine.

To a stirred solution of amine (0.357 g, 1.28 mmol) and cyclopentanone (0.15 mL, 1.67 mmol) in methylene chloride (5 mL) was added sodium triacetoxyborohydride (0.546 g, 2.57 mmol), acetic acid (0.15 mL, 2.57 mmol) and stirred at rt for 24 h. The reaction mixture was quenched with aqueous NaOH and extracted with methylene chloride. The combined extracts were dried, concentrated and chromatographed to yield 0.376 g (85%) of amine as a solid.

To a stirred solution of amine (0.300 g, 0.869 mmol) and triethyl amine (0.600 mL, 4.34 mmol) in methylene chloride was added 3,5-dichlorophenyl isocyanate (0.817 g, 4.34 mmol) and stirred at rt for 24 h. The reaction mixture was then diluted with methylene chloride, washed with aqueous NaOH, dried, concentrated and chromatographed to yield 0.24 g (52%) of urea as a solid.

300 MHz- ^1H NMR (CDCl_3) δ 7.86 (s, 1 H), 7.79-7.82 (m, 1H), 7.59-7.69 (m, 4H), 7.31 (d, $J = 8.4$ Hz, 2H), 7.23 (m, 2 H), 7.20 (s, 1 H), 5.99 (s, 1 H), 4.52-4.60 (m, 1 H), 3.07 (m, 2H), 2.46 (m, 1H), 2.09 (m, 2H), 1.89 (m, 4 H), 1.27-1.63 (m, 9 H).
HRMS ($\text{M}+\text{H}^+$) 533.1867


20





EXAMPLES 2-43





Employing preparative procedures similar to those described in Example 1, the following compounds shown below in Table 1 were prepared.





25

TABLE I





<u>Ex.</u>	<u>Structure/Name</u>	<u>HRMS</u>	<u>300MHZ-^1H NMR CDCl_3, δ</u>
2	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-(1-cyclopentyl-4-piperidiny)-N'-[(3,5-</p>	547.2036	





	dichlorophenyl) methyl]urea		
3	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-(4-piperidinyl)urea</p>	465.1255	
4	 <p>N-[3'-chloro[1,1'-biphenyl]-4-yl]-N-(1-cyclopentyl-4-piperidinyl)-N'-(3,5-dichlorophenyl)urea</p>	542.1529	
5	 <p>N-(1-cyclopentyl-4-piperidinyl)-N'-(3,5-dichlorophenyl)-N-[4-(3-pyridinyl)phenyl]urea</p>	509.1869	
6	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-(1-cyclopentyl-4-piperidinyl)-N'-(3,4-difluorophenyl)urea</p>	501.2473	





7	 <p>N-[3'-cyano[1,1'-biphenyl]4-yl]- N-(1-cyclopentyl-4-piperidinyl)- N'-(3,4-dichlorophenyl)urea</p>	533.1867	7.80-7.87 (m, 3H), 7.58-7.71 (m, 4H), 7.49 (d, J=3 Hz, 1H), 7.46 (d, J=9.0 Hz, 2H), 7.26 (s, 1H), 7.06-7.10 (m, 1 H), 5.92 (s, 1H), 4.59 (m, 1H), 3.08(m, 2H), 2.46 (m, 1 H), 2.09 (m, 2 H), 1.89 (m, 4 H), 1.27-1.63 (m, 8 H).
8	 <p>N'-(3-chlorophenyl)-N-[3'- cyano[1,1'-biphenyl]4-yl]-N-(1- cyclopentyl-4-piperidinyl)urea</p>	499.2269	
9	 <p>N'-(3-chloro-4-fluorophenyl)-N- [3'-cyano[1,1'-biphenyl]4-yl]- N-(1-cyclopentyl-4- piperidinyl)urea</p>	517.2165	
10	 <p>N-[3'-cyano[1,1'-biphenyl]4- yl]-N'-(3,5-dichlorophenyl)-N(1- methyl-4-piperidinyl)urea</p>	479.1400	





11	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-(1-propyl-4-piperidiny)urea</p>	507.1709	
12	 <p>N-[1-[(1,4-benzodioxin-6-yl)methyl]-4-piperidiny]-N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)urea</p>	613.1779	
13	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidiny]urea</p>	549.1832	
14	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[1-(2-pyridinylmethyl)-4-piperidiny]urea</p>	556.1672	

- 37 -



15	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl] -N-(1-cyclopentyl-4-piperidiny) -N'-(2,6-dichloro-4-pyridinyl)urea</p>	534.1823	
16	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl] -N-(1-cyclopentyl-4-piperidiny) -N'-(4-fluoro-3-(trifluoromethyl)phenyl)urea</p>	551.2443	7.79-7.86(m, 2H), 7.52-7.70 (m, 5H), 7.40(m, 1H), 7.35 (d, J=9.0 Hz, 2H), 7.04 (t, J=9.0 Hz, 1H), 5.97 (s, 1H), 4.59(m, 1H), 3.09 (m, 2H), 2.45 (m, 1H), 2.11 (m, 2H), 1.87(m, 4H), 1.24-1.65(m, 8H)
17	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]urea</p>	476.1043	
18	 <p>N-[4'-[1-cyclopentyl-4-piperidiny]l]l[(3,5-dichlorophenyl)amino]carbonyl]amino[1,1'-biphenyl]-3-yl]acetamide</p>	565.2145	7.83 (s, 1 H), 7.62 (d, J=9.0 Hz, 2 H), 7.38-7.47 (m, 2 H), 7.28 (m, 6 H), 7.15 (d, J = 9.0 Hz, 2 H), 6.95 (s, 1 H), 6.11 (s, 1 H), 4.56 (m, 1 H), 3.09 (m, 2 H), 2.45 (m, 1 H), 2.21 (s, 3 H), 2.13 (m, 2 H), 1.87 (m, 4 H), 1.36-1.66 (8 H)




19	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-(1-cyclopentyl-4-piperidiny)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea</p>	551.2427	
20	 <p>N-[4'-(1-cyclopentyl-4-piperidiny)][(3,5-dichlorophenyl)amino]carbonyl]amino[1,1'-biphenyl]-3-yl]methanesulfonamide</p>	601.1798	
21	 <p>N-(1-cyclopentyl-4-piperidiny)-N'-(3-chloro-4-fluorophenyl)-N-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]urea</p>	576.2035	
22	 <p>N-[[1-(cyclopropylmethyl)-4-piperidiny]methyl]-N'-(3,5-dichlorophenyl)-N-[4-(3-pyridinyl)phenyl]urea</p>	509.1879	8.90 (s, 1 H); 8.66(d, J = 3.6 Hz, 1 H); 7.92(d, J=8.2 Hz, 2 Hz, 2 H); 7.72 (d, J=8.2 Hz; 2 H); 7.45, 7.40 (m, 2 H); 7.27 (s, 2 H); 6.98 (d, J= 1.7 Hz, 1 H); 6.28 (s, 1 H); 3.70 (d, J= 6.9 Hz, 2 H); 3.13-3.08(m,2H);2.29(d, J =5.5 Hz, 2H);2.06-2.02(m,2H);1.99-1.70 (m, 3 H); 1.50-1.41 (m, 2 H); 0.90 (m, 1 H); 0.55-0.49 (m, 2 H); 0.12-0.10 (m, 2 H).








23	 <p>N-[3'-chloro[1,1'-biphenyl]-4-yl]-N-[(1-cyclopentyl-4-piperidinyl)methyl]-N'-(3,5-dichlorophenyl)urea</p>	558.1667	7.68 (d, J = 8.1 Hz, 2 H); 7.62 (s, 1 H); 7.52-7.45 (m, 5 H); 7.38 (s, 2 H); 6.97 (d, J = 1.7 Hz, 1 H); 6.24 (s, 1 H); 3.67 (d, J = 6.6 Hz, 2 H); 3.03 (d, J = 11.0 Hz, 2 H); 2.49 (m, 1 H); 2.01-1.26 (m, 15 H).
24	 <p>N-[3'-chloro[1,1'-biphenyl]-4-yl]-N-(1-cyclopentyl-3-pyrrolidinyl)-N'-(3,5-dichlorophenyl)urea</p>	530.1354	7.60-7.27 (m, 11 H); 6.97 (s, 1 H); 4.48 (m, 2 H); 3.33-3.30 (m, 2 H); 2.63-2.58 (m, 2 H); 2.50 (m, 1 H); 2.48-2.25 (m, 2 H); 2.00-1.26 (m, 8 H).
25	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-[2-(1-cyclopentyl-4-piperidinyl)ethyl]-N'-(3,5-dichlorophenyl)urea</p>	561.2125	7.91 (t, J = 1.4 Hz, 1 H); 7.86 (m, 1 H); 7.70 (d, J = 8.5 Hz, 2 H); 7.69 (m, 1 H); 7.61 (t, J = 7.6 Hz, 1 H); 7.39 (d, J = 8.5 Hz, 2 H); 7.26 (s, 2 H); 6.98 (d, J = 1.8 Hz, 1 H); 6.18 (s, 1 H); 3.80 (t, J = 7.1 Hz, 2 H); 3.28-3.10 (m, 2 H); 2.68 (m, 1 H); 2.20-2.11 (m, 2 H); 1.94-1.38 (m, 15 H).
26	 <p>N-[3'-chloro[1,1'-biphenyl]-4-yl]-N'-(3-chloro-4-fluorophenyl)-N-(1-cyclopentyl-4-piperidinyl)urea</p>	526.1824	

27	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[4-(dimethylamino)cyclohexyl]urea (isomer A)</p>	507.1724	
28	 <p>N-[6-(3-cyanophenyl)-3-pyridinyl]-N-(1-cyclopentyl-4-piperidiny)-N'-(3,5-dichlorophenyl)urea</p>	534.1831	
29	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-(1-cyclopentyl-4-piperidiny)-N'-(3,5-dichlorophenyl)thiourea</p>	549.1633	
30	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[1-(3-pyridinylmethyl)-4-piperidiny]urea</p>	556.1678	


- 41 -


31	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[2-[(2-pyridinyl)methyl]amino]ethylurea</p>	534.1917	
32	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[2-[(2-methoxyethyl)amino]ethylurea</p>	501.1921	

Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃
33		554.1809	
34		547.2036	
35		533.1867	

36		565.2595	7.86 (s, 1 H), 7.85 (d, $J = 7.8$ Hz, 1H), 7.71 (m, 1 H), 7.70 (d, $J = 8.4$ Hz, 2 H), 7.60 (t, $J = 7.5$ Hz, 1 H), 7.52 (d, $J = 3.0$ Hz, 1 H), 7.50 (d, $J = 3.0$ Hz, 1 H), 7.43 (d, $J = 8.4$ Hz, 2 H), 7.07 (t, $J = 9.9$ Hz, 1 H), 6.27 (s, 1 H), 3.69 (d, $J = 6.3$ Hz, 2 H), 3.04 (d, $J = 11.1$ Hz, 2 H), 2.50 (m, 1 H), 2.25 (s, 1 H), 1.98 (t, $J = 11.1$ Hz, 2 H), 1.85 - 1.68 (m, 6 H), 1.57 - 1.38 (m, 6 H)
37		551.2443	
38		539.2435	
39		565.2592	7.90 (s, 1 H), 7.85 (dt, $J = 8.1, 1.5, 1.2$ Hz, 1H), 7.72 (m, 1 H), 7.71 (d, $J = 8.4$ Hz, 2 H), 7.61 (t, $J = 7.8$ Hz, 1 H), 7.52 (d, $J = 3.6$ Hz, 1 H), 7.50 (d, $J = 2.7$ Hz, 1 H), 7.43 (d, $J = 8.4$ Hz, 2 H), 7.08 (t, $J = 9.6$ Hz, 1 H), 6.20 (s, 1 H), 3.82 (t, $J = 7.5$ Hz, 2 H), 3.08 (d, $J = 11.1$ Hz, 2 H), 2.27 (d, $J = 6.6$ Hz, 2 H), 1.98 (t, $J = 10.5$ Hz, 2 H), 1.74 - 1.71 (m, 2 H), 1.56 - 1.53 (m, 2 H), 1.35 - 1.25 (m, 3 H), 0.88 (m, 1 H), 0.54 - 0.48 (m, 2 H), 0.10 (q, $J = 5.1$ Hz, 2 H)
40		505.2172	
41		519.2350	
42		521.1872	

- 43 -

43		491.1493	
----	---	----------	--

EXAMPLE 44

5

N-3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-
N-[2-(propylamino)ethyl]urea

To a solution of 4-bromoaniline (16.86 g, 98.0 mmol) in toluene (40 ml) was
 10 added 2-bromoethylamine hydrobromide (10.0 g, 49.0 mmol) and heated to 110°C for
 4 h. The reaction mixture was then cooled to rt and poured into water (60 mL) and
 50% KOH (20 mL). The layers were separated and the aqueous layer is then
 extracted with toluene. The combined organic layer was then dried, concentrated and
 chromatographed over silica gel (eluting with 90% MeOH/methylene chloride and 1%
 15 NH₄OH) to afford 8.41 g (40%) of diamine.

To a solution of amine (8.41 g, 39.11 mmol) in methylene chloride (200 mL)
 was added DMAP (5 mg) followed by drop-wise addition of BOC₂O (8.53 g, 39.11
 mmol in methylene chloride) over 45 min and stirred for 1 h at rt. The reaction mixture
 was then poured into 10% NaOH and extracted with methylene chloride, dried,
 20 concentrated to yield 12.44 g (100%) of mono BOC-protected amine as a solid.

To a stirred solution of amine (5.36 g, 17.01 mmol) in 40 mL of DME:H₂O (4:1)
 was added 3-cyanophenylboronic acid (5.00g, 34.03 mmol), PdCl₂(PPh₃)₂ (1.19 g,
 1.70 mmol), Na₂CO₃ (5.41 g, 51.05 mmol) and heated to 80°C for 24h. The reaction
 mixture was then cooled to rt, poured into aqueous NaOH and extracted with ether.

- 44 -

The combined extracts were then dried, concentrated and chromatographed to yield 1.1 g (19%) of biaryl amine as a solid.

To a stirred solution of amine (0.300 g, 0.890 mmol) and triethyl amine (0.620 mL, 4.45 mmol) in methylene chloride (5 ml) was added 3,5-dichlorophenyl isocyanate (0.837 g, 4.45 mmol) and stirred at rt for 24 h. The reaction mixture was then diluted with methylene chloride, washed with aqueous NaOH, dried, concentrated and chromatographed to yield 0.49 g (100%) of urea as an oil. To a stirred solution of biaryl amine (0.490 g, 0.89 mmol) in methylene chloride (5 mL) was added trifluoroacetic acid (1.3 mL) and stirred at rt for 2 h. The reaction mixture was concentrated and poured into 10% NaOH and extracted with methylene chloride. The combined extracts were dried and concentrated to afford 0.35 g (92%) of amine.

To stirred solution of amine (0.075 g, 0.23 mmol) and propionaldehyde (0.016 mL, 0.23 mmol) in methylene chloride (2 mL) was added sodium triacetoxyborohydride (0.054 g, 0.254 mmol), acetic acid (0.015 mL, 0.254 mmol) and stirred at rt for 24 h. The reaction mixture was quenched with aqueous NaOH and extracted with methylene chloride. The combined extracts were dried, concentrated and chromatographed to yield 0.026 g (25%) of amine as a solid.

300 MHz – ^1H NMR (CDCl_3) δ 7.86 (s, 1 H), 7.79-7.82 (m, 1 H), 7.54-7.68 (m, 4H), 7.41 (d, J = 8.4 Hz, 2 H), 7.35 (m, 2 H), 6.96 (m, 1 H), 3.88 (t, J = 5.4 Hz, 2 H), 2.92 (t, J = 5.7 Hz, 2 H), 2.68 (t, J = 7.5 Hz, 2 H), 1.52- 1.63 (m, 3 H), 0.95 (t, J = 7.5 Hz, 3 H).





HRMS ($\text{M}+\text{H}^+$) 467.1400




EXAMPLES 45-73




Employing preparative procedures similar to those described in Example 44, the following compounds shown below in Table II were prepared.





TABLE II



Ex.	Structure/Name	HRMS	300MHZ- ^1H NMR CDCl_3 , δ
-----	----------------	------	---



Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
45	 N-[3'-cyano[1,1'-biphenyl]-4-yl] -N-[2-(cyclopentylamino)ethyl] -N'-(3,5-dichlorophenyl)urea	493.1562	
46	 N'-(3-chloro-4-fluorophenyl)-N-[3'-cyano[1,1'-biphenyl]-4-yl]- N-[2-(dimethylamino)ethyl]urea	437.1548	7.80-7.86 (m, 3 H), 7.60-7.66 (m, 5 H), 7.41 (d, J = 9.0 Hz, 2 H), 7.11 (m, 1 H), 7.01 (t, J = 8.7 Hz, 1 H), 3.89 (t, J = 5.4 Hz, 2 H), 2.63 (t, J = 5.4 Hz, 2 H), 2.40 (s, 6 H)
47	 N-(2-aminoethyl)-N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(4-fluoro-3-(trifluoromethyl)phenyl)urea	443.1490	
48	 N-[3'-cyano[1,1'-biphenyl]-4-yl] -N'-(4-fluoro-3-(trifluoromethyl)phenyl)-N-[2- phenyl]-N-[2-	485.1960	7.87-7.80 (m, 3 H), 7.55-7.66 (m, 6 H), 7.47 (d, J = 9.0 Hz, 2 H), 7.09 (t, J = 10.0 Hz, 1 H), 3.96 (t, J = 5.4 Hz, 2 H), 2.98 (t, J = 5.7 Hz, 2 H), 2.75 (t, J = 7.2 Hz, 2 H), 2.50 (m, 1 H), 1.59-1.66 (m, 3 H), 0.96 (t, J = 7.5 Hz, 3 H).








Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ δ
	(propylamino)ethyl]urea		
49	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[2-[methyl(propyl)amino]ethyl]urea</p>	481.1553	
50	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-[2-[(cyclopropylmethyl)amino]ethyl]-N'-(3,5-dichlorophenyl)urea</p>	479.1400	
51	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[3-[(dipropylamino)propyl]urea</p>	523.2023	

Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
52	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-[2-[(cyclopropylmethyl)amino]ethyl]-N'-(3,5-difluorophenyl)urea</p>	447.1992	
53	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3-chloro-4-fluorophenyl)-N-[3-(dimethylamino)propyl]urea</p>	451.1706	9.40 (s, 1 H), 7.79-7.86 (m, 2 H), 7.56-7.63 (m, 5 H), 7.39 (d, J = 9.0 Hz, 2 H), 7.17 (m, 1 H), 7.03 (t, J = 8.7 Hz, 1 H), 3.90 (t, J = 6.0 Hz, 2 H), 2.48 (t, J = 6.6 Hz, 2 H), 2.34 (s, 6 H), 1.75 (t, J = 6.0 Hz, 2 H)
54	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3-chloro-4-fluorophenyl)-N-[2-(diethylamino)]ethyl]urea</p>	465.1853	





Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ δ
55	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3-chloro-4-fluorophenyl)-N-[2-(diethylamino)propyl]urea</p>	479.2007	
56	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-[2-[(cyclopropylmethyl)amino]ethyl]-N'-(4-fluoro-3-(trifluoromethyl)phenyl)urea</p>	497.1971	8.90 (s, 1 H), 7.86-7.80 (m, 2H), 7.55-7.66 (m, 6 H), 7.58 (d, J = 8.1 Hz, 2 H), 7.08 (t, J = 9.3 Hz, 1 H), 3.93 (t, J = 5.4 Hz, 2 H), 2.98 (t, J = 5.7 Hz, 2 H), 2.60 (t, J = 6.9 Hz, 2 H), 2.20 (m, 1 H), 1.00 (m, 1 H), 0.53 (m, 2 H), 0.18 (m, 2 H)
57	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(4-fluoro-3-(trifluoromethyl)phenyl)-N-[2-[(3,3,3-trifluoropropyl)amino]ethyl]urea</p>	539.1691	
58		485.1964	


Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
	N-[3'-cyano[1,1'-biphenyl]-4-yl] -N'-[3-fluoro-4-(trifluoromethyl) phenyl]-N-[2-(propylamino) ethyl]urea		
59	 N-[3'-chloro[1,1'-biphenyl]-4-yl] -N'-(3-chloro-4-fluorophenyl)- N-[2-(dimethylamino)ethyl]urea	446.1195	
60	 N'-(3-chloro-4-fluorophenyl)-N-[2-(dimethylamino)ethyl]-N-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]urea	496.1410	

Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃
61		544.1837	
62		526.1270	

63		471.1810	
64		467.1409	
65		485.1970	
66		475.1821	
67		479.1403	
68		463.1702	
69		451.1692	

- 51 -

70		485.1969	
71		465.1858	
72		515.1823	
73		517.2171	

EXAMPLE 74

5

N-[3'-cyano[1,1'-biphenyl]-4-yl]-N-(3,5-dichlorophenyl)
-N-[2-(1-piperidinyl)ethyl]urea

- 52 -

To a stirred solution of 4-bromoaniline (10.0 g, 58.1 mmol) in 500 mL of DME:H₂O (4:1) was added 3-cyanophenylboronic acid (13.3 g, 91.2 mmol), PdCl₂dppf (4.72 g, 5.86 mmol), 2N Na₂CO₃ (100 mL) and heated to 100°C for 5 h. The reaction mixture was then cooled to rt, poured into aqueous NaOH and extracted with EtOAc. The combined extracts are then dried, concentrated and chromatographed to yield 7.4 g (66%) of biaryl amine as a solid.

To a stirring solution of biaryl aniline (4.49 g, 23.14 mmol) and chloroacetaldehyde (2.18 g, 27.77 mmol) in 4 mL of 1:1 of 6M HCl:MeOH in MeOH (60 mL) was added sodium cyanoborohydride (1.63 g, 25.92 mmol). The reaction mixture was then stirred at rt for 5 days, concentrated, diluted with methylene chloride and washed with NaHCO₃, dried, concentrated and chromatographed to yield 4.19 g (67%) of chloride as a solid.

To a stirred solution of chloride (0.350 g, 1.28 mmol) in propionitrile (10 mL) was added piperidine (0.546 mL, 6.43 mmol), NaI (0.19, 1.28 mmol), Na₂CO₃ (0.203 g, 1.92 mmol) and heated to 80°C for 12 h. The reaction mixture was then cooled to rt and diluted with EtOAc and water. The layers were separated and the organic layer is then dried, concentrated and chromatographed to yield 0.32 g (78%) as an oil.




To a stirred solution of amine (0.04 g, 0.124 mmol) and triethyl amine (0.038 mL, 0.372 mmol) in methylene chloride (2 mL) was added 3,5-dichlorophenyl isocyanate (0.069 g, 0.372 mmol) and stirred at rt for 24 h. The reaction mixture was then diluted with methylene chloride, washed with aqueous NaOH, dried, concentrated and chromatographed to yield 0.048 g (63%) of urea as an oil.





EXAMPLES 75-200



25



Employing preparative procedures similar to those described in Example 74, the following compounds shown below in Table III were prepared:








TABLE III








Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
75	 N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[2-(1-pyrrolidinyl)ethyl]urea	479.1400	
76	 N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]urea	585.1816	
77	 N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]urea	508.1664	7.81-7.86 (m, 3 H), 7.58-7.66 (m, 5 H), 7.43 (d, J = 8.7 Hz, 2 H), 7.36 (m, 1 H), 6.98 (m, 1 H), 3.89 (t, J = 5.7 Hz, 2 H), 2.63 (m, 7 H), 2.49 (s, 4 H), 2.31 (s, 3 H)







Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
78	 <p>N-[1-[2-[[3'-cyano[1,1'-biphenyl]-4-yl]][(3,5-dichlorophenyl)amino]carbonyl]amino]ethyl]-3-pyrrolidiny]acetamide</p>	536.1630	
79	 <p>N-[1-[2-[[3'-cyano[1,1'-biphenyl]-4-yl]][(3,5-dichlorophenyl)amino]carbonyl]amino]ethyl]-3-pyrrolidiny]methanesulfonamide</p>	572.1296	
80	 <p>1-[2-[[3'-cyano[1,1'-biphenyl]-4-yl]][(3,5-dichlorophenyl)amino]carbonyl]amino]ethyl]-4-(methanesulfonyl)piperidinamine</p>	572.1284	
81	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[2-(1-piperidiny)ethyl]urea</p>	511.2121	








Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
82	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3-fluoro-5-(trifluoromethyl)phenyl)-N-[2-(1-piperidinyl)ethyl]urea</p>	511.2121	
83	 <p>N-[3'-cyano[1,1'-biphenyl]-4-yl]-N'-(3,5-dichlorophenyl)-N-[2-[4-(ethoxyimino)-1-piperidinyl]ethyl]urea</p>	550.1972	







Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃ , δ
84		487.1514	
85		471.1810	







86		454.1212	
87		536.1986	8.07 (s, 1H), 7.87-7.80 (m, 2H), 7.68-7.58 (m, 4H), 7.43 (d, J = 9.3 Hz, 2H), 7.38 (d, J = 2.0 Hz, 2H), 6.98 (d, J = 2.0 Hz, 1H), 3.89 (t, J = 6.3 Hz, 2H), 2.66-2.62 (m, 4H), 2.53 (m, 2H), 2.36-2.31 (m, 2H) 1.53-1.50 (m, 2H), 0.90 (t, J = 8.3 Hz, 3H)
88		522.1820	
89		534.2066	
90		568.2345	
91		451.1700	
92		536.1622	7.86-7.80 (m, 2H), 7.66 (d, J = 9.3 Hz, 2H), 7.61-7.55 (m, 2H), 7.42 (d, J = 9.3 Hz, 2H), 7.28 (d, J = 2 Hz, 2H), 7.13 (s, 1H), 6.95 (s, 1H), 6.18 (d, J = 8.3 Hz, 1H), 4.36-4.34 (m, 1H), 4.06-3.99 (m, 1H), 3.74-3.64 (m, 1H), 2.98-2.91 (m, 1H), 2.83-2.49 (m, 4H), 2.35-2.22 (m, 2H), 1.86 (s, 3H), 1.67-1.63 (m, 1H)







93		536.1622		
94		492.1966		
95		526.2232		
96		562.2142		
97		548.2018		
98		552.1935		
99		554.2546		







100		520.1911	
101		554.2173	
102		564.1938	
103		578.2097	
104		550.1784	
105		565.1887	








106		522.1820	
107		586.1770	
108		579.2042	
109		495.1353	
110		479.1657	
111		513.1913	8.22 (s, 1H), 7.86-7.80 (m, 2H), 7.67-7.54 (m, 6H), 7.44 (d, J = 9.3 Hz, 2H), 7.07 (t, J = 10.3 Hz, 1H), 4.42-4.38 (m, 1H), 3.91 (t, J = 6.3 Hz, 2H), 3.07-3.01 (m, 1H), 2.87-2.84 (m, 1H), 2.79 (t, J = 6.3 Hz, 2H), 2.65-2.60 (m, 1H), 2.46-2.38 (m, 1H), 2.29-2.14 (m, 2H), 1.81-1.77 (m, 1H)
112		554.2189	







113		No HRMS		
114		483.1801		
115		554.2150		
116		564.1933		
117		550.1795		
118		467.1648		







119		521.1782	
120		483.2002	
121		565.1876	
122		509.1519	
123		493.1803	
124		579.2051	







125		579.2051	
126		566.1717	
127		581.1665	
128		527.2070	
129		527.2078	
130		503.1465	







131		454.1849	
132		497.1961	
133		542.2179	
134		No HRMS	
135		513.1923	8.55 (s, 1H), 7.87-7.80 (m, 2H), 7.68-7.53 (m, 5H), 7.46-7.38 (m, 3H), 7.11 (d, $J = 10.0$ Hz, 1H), 4.45-4.41 (m, 1H), 3.92 (t, $J = 6.3$ Hz, 2H), 3.11-3.04 (m, 1H), 2.95-2.86 (m, 1H), 2.82 (t, $J = 6.3$ Hz, 2H), 2.68-2.63 (m, 1H), 2.49-2.41 (m, 1H), 2.27-2.15 (m, 2H), 1.87-1.79 (m, 1H)
136		499.2128	

137		534.2073	
138		568.2324	
139		541.2228	
140		437.1548	
141		597.2611	
142		568.2346	
143		550.2014	







144		583.2457		
145		584.2292		
146		487.1756		
147		437.940		
148		527.2077		
149		493.1803		








150		538.1772	
151		526.2224	
152		506.1769	
153		511.2128	
154		525.2289	7.85-7.78 (m, 2H), 7.67-7.53 (m, 6H), 7.42 (d, $J = 12.3$ Hz, 2H), 7.12 (t, $J = 10.6$ Hz, 1H), 4.01 (t, 2H), 2.87 (t, 2H), 2.68 (m, 2H), 2.04 (m, 2H), 1.56 (m, 2H), 1.27 (d, 6H)
155		525.2284	







156		520.2288		
157		550.1784		
158		525.2289		
159		574.1459	7.84 (d, J = 7.7 Hz, 1 H), 7.67 (m, 3 H), 7.59 (t, J = 7.7 Hz, 1 H), 7.47 (d, J = 8.2 Hz, 2 H), 7.28 (d, J = 1.8 Hz, 2 H), 6.97 (t, J = 1.8 Hz, 1 H), 3.87 (t, J = 6.2 Hz, 2 H), 3.26 (t, J = 6.6 Hz, 2 H), 2.89 (s, 3 H), 2.81 (s, 3 H), 2.67 (m, 4 H), 2.35 (s, 3 H)	
160		455.1452		
161		438.1502		







162		514.1873	
163		493.1803	
164		527.2080	
165		540.2377	
166		511.1753	
167		590.1848	


[illegible]

175		554.2177		
176		540.2390		
177		527.2072		
178		540.2385		
179		540.2385		
180		515.1877		

181		594.2497	
182		554.2543	
183		578.2097	
184		568.2334	
185		604.2011	
186		541.2223	7.87-7.81 (m, 3H), 7.69-7.56 (m, 6H), 7.46 (d, $J = 12.3$ Hz, 2H), 7.08 (t, $J = 11.0$ Hz, 1H), 3.92 (t, $J = 6.6$ Hz, 2H), 3.13-3.08 (m, 1H), 2.87-2.78 (m, 3H), 2.47-2.39 (m, 2H), 1.91-1.84 (m, 1H), 1.63 (q, $J = 8.3$ Hz, 2H), 1.29-1.21 (m, 2H), 0.97 (t, $J = 8.3$ Hz, 3H)
187		555.2374	


188		529.1626	
189		513.1908	
190		545.1573	
191		496.1304	
192		538.2238	7.86-7.80 (m, 2H), 7.67-7.54 (m, 6H), 7.44 (d, $J = 9.3$ Hz, 2H), 7.09 (t, $J = 10.3$ Hz, 1H), 3.88-3.83 (m, 2H), 3.42-3.32 (m, 2H), 2.95-2.88 (m, 3H), 2.82-2.78 (m, 2H), 2.61-2.57 (m, 1H), 2.42 (s, 3H), 1.82 (d, $J = 11.3$ Hz, 1H), 1.71 (d, $J = 11.3$ Hz, 1H)
193		513.1914	

194		562.1785	
195		605.2082	
196		618.2170	
197		618.2170	
198		659.1789	
199		619.2106	

200		571.2079	
-----	---	----------	--

The following example illustrates the preparation of compounds using method 4:

5

EXAMPLE 201

To a stirred solution of 4-bromoaniline (9.4 g, 54.82 mmol) in 250 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (16.11 g, 109.65 mmol), Pd(PPh₃)₄ (6.3 g, 5.48 mmol) and Na₂CO₃ (35 g, 330 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed to yield 4.78 g (45%) of biaryl aniline.

To a stirred solution of biaryl aniline (2.37 g, 12.2 mmol) and 1-chloro-3-iodopropane (1.45 mL, 13.4 mmol) in DMF (20mL) was added K₂CO₃ (3.38 g, 24.4 mmol). The reaction mixture stirred at rt for 3 days, concentrated, diluted with methylene chloride and washed with aqueous NaOH, dried, concentrated and chromatographed to yield 0.94 g (29%) of chloride.

To a solution of the chloride (0.48 g, 1.77 mmol) in acetonitrile (3 mL) was added (3R)-(+)-3-acetamidopyrrolidine (0.68 g, 5.31 mmol), NaI (0.26 g, 1.77 mmol) and Na₂CO₃ (0.28 g, 2.65 mmol) and heated to 90°C for 24 h. The reaction mixture was cooled to rt, diluted with EtOAc, washed with water, aqueous NaOH, dried, concentrated and chromatographed to yield 0.64 g (100%) of amine as a solid.

To a stirred solution of amine (0.100 g, 0.276 mmol) and triethyl amine (0.077 mL, 0.552 mmol) in methylene chloride (1 mL) was added 3,5-dichlorophenyl isocyanate (0.104 g, 0.552 mmol) and stirred at rt for 24 h. The reaction mixture was

- 75 -

then diluted with methylene chloride, washed with water, aqueous NaOH, dried, concentrated and chromatographed to yield 0.084 g (55%) of urea.

300 MHz- ^1H NMR (CDCl_3) δ 7.87-7.82 (m, 2H), 7.68-7.56 (m, 4H), 7.40 (d, J = 9.0 Hz, 2H), 7.31 (s, 2H), 6.98 (s, 1H), 6.15 (d, J = 8.3 Hz, 1H), 4.44 (m, 1H), 3.97-3.47 (m, 3H), 2.93 (m, 1H), 2.65-2.54 (m, 4H), 2.33-2.27 (m, 2H), 1.95 (s, 3H), 1.95-1.79 (m, 2H)

HRMS ($\text{M}+\text{H}^+$): 550.1795





EXAMPLES 202-208

10




Employing preparative procedures similar to those described in Example 201, the following compounds shown below in Table IV were prepared:

Table IV

15


<u>Ex.</u>	<u>Structure/Name</u>	<u>HRMS</u>	<u>300MHZ-^1H NMR CDCl_3</u>
202		534.3035	
203		568.2374	
204		511.2128	
205		511.2133	

- 76 -

206		463.1698	7.84-7.78 (m, 2H), 7.71-7.68 (m, 1H), 7.65-7.55 (m, 4H), 7.38-7.34 (m, 3H), 7.05 (t, $J = 10.0$ Hz, 1H), 3.86 (t, $J = 6.6$ Hz, 2H), 3.32 (m, $J = 8.0$ Hz, 4H), 2.61 (t, $J = 6.6$ Hz, 2H), 2.21 (m, $J = 8.0$ Hz, 2H), 1.61 (m, $J = 6.66$ Hz, 2H)
207		497.1962	
208		527.2068	

5. The following example illustrates the preparation of compounds using method

5

EXAMPLE 209

To a stirred solution of 4-bromoaniline (9.4 g, 54.82 mmol) in 250 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (16.11 g, 109.65 mmol), Pd(PPh₃)₄ (6.3 g, 5.48 mmol) and Na₂CO₃ (35 g, 330 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed to yield 4.78 g (45%) of biaryl aniline.

To a stirred solution of biaryl aniline (4.49 g, 23.14 mmol) and chloroacetaldehyde (2.18 g, 27.77 mmol) in 4 mL of 1:1 of 6M HCl:MeOH in MeOH (60mL) was added sodium cyanoborohydride (1.63 g, 25.92 mmol). The reaction

- 77 -

mixture stirred at rt for 5 days, concentrated, diluted with methylene chloride and washed with NaHCO₃, dried, concentrated and chromatographed to yield 4.19 g (67%) of chloride as a solid.

To a solution of the chloride (1.39 g, 5.35 mmol) in 2M methylamine solution in THF (50 mL) was added NaI (0.80 g, 5.35 mmol) and Na₂CO₃ (1.13 g, 10.7 mmol) and heated to 90°C for 12 h. Cooled to rt and filtered off solids and concentrated filtrate. Chromatographed to yield 1.34 g (100%) of amine as a solid.

To a stirred solution of amine (1.34 g, 5.35 mmol) in EtOAc (100 mL) was added 10% aqueous NaOH (100 mL) and di-*tert*-butyl dicarbonate and stirred at rt for 3 h. The layers were separated and the organic layer was dried over Na₂SO₄ and concentrated to yield 1.76 g (94%) BOC protected amine.

To a stirred solution of amine (0.087 g, 0.248 mmol) and triethyl amine (0.069 mL, 0.496 mmol) in methylene chloride (1 mL) was added 4-fluoro-3-trifluoromethylphenyl isocyanate (0.071 mL, 0.496 mmol) and stirred at rt for 24 h. The reaction mixture was then diluted with methylene chloride, washed with aqueous NaOH, dried, concentrated and chromatographed to yield 0.97 g (63%) of urea.

To a stirred solution of urea (0.97 g, 0.174 mmol) in methylene chloride (3 mL) was added trifluoroacetic acid (0.134 mL, 1.74 mmol) and stirred under N₂ at rt for 18 h. The reaction mixture was concentrated, then diluted with methylene chloride and washed with aqueous NaOH, dried, concentrated and chromatographed to yield 0.041 g (52%) of the secondary amine.

300 MHz- ¹H NMR (CDCl₃) δ 7.86-7.80 (m, 2H), 7.68-7.52 (m, 7H), 7.44 (d, J = 9.3 Hz, 2H), 7.08 (t, J = 10.3 Hz, 1H), 3.92 (t, J = 6.0 Hz, 2H), 2.92 (t, J = 6.0 Hz, 2H), 2.55 (s, 3H), 2.12 (s, 1H)

HRMS (M+H⁺): 457.1647

EXAMPLES 210-221







Employing preparative procedures similar to those described in Example 209, the following compounds shown below in Table V were prepared:







30

Table V

<u>Ex.</u>	<u>Structure</u>	<u>HRMS</u>	<u>300MHZ-¹H NMR CDCl₃</u>
------------	------------------	-------------	--


- 78 -

210		483.1815	7.88-7.81 (m, 3H), 7.69-7.51 (m, 6H), 7.44 (d, $J = 12.0$ Hz, 2H), 7.08 (t, $J = 10.6$ Hz, 1H), 3.91 (t, $J = 6.6$ Hz, 2H), 3.00 (t, $J = 6.3$ Hz, 2H), 2.26-2.22 (m, 1H), 1.97 (s, 1H), 0.52-0.37 (m, 4H)
211		472.2017	
212		438.1744	
213		516.0859	
214		457.1642	
215		457.1647	

216		437.1553	
217		471.1818	
218		471.1813	
219		511.1309	
220		499.2130	
221		559.2337	

The following example illustrates the preparation of compounds using method 6.

- 80 -

EXAMPLE 222

To a stirred solution of 4-bromoaniline (9.4 g, 54.82 mmol) in 250 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (16.11 g, 109.65 mmol), Pd(PPh₃)₄ (6.3 g, 5.48 mmol) and Na₂CO₃ (35 g, 330 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed to yield 4.78 g (45%) of biaryl aniline.

A solution of biaryl aniline (2.2 g, 11.4 mmol) in titanium isopropoxide (4.25 mL, 14.25 mmol) was treated with γ -butyrolactol (1.0 g, 11.4 mmol) and stirred at rt for 40 h. The reaction mixture was diluted with methanol (5 mL), NaCNBH₃ (0.93 g, 14.8 mmol) was added and stirred for 24 h. H₂O (3 mL) was added and the suspension stirred for 30 min. The suspension was filtered through celite, rinsed with MeOH and concentrated. The residue was dissolved in EtOAc, dried over MgSO₄, filtered and concentrated. The crude amino-alcohol (4.0 g) was used directly for the following step.

A solution of amino-alcohol (4.0 g) in THF/MeOH/H₂O (4:1:1, 50 mL) was treated with sodium bicarbonate (1.70 g, 20.2 mmol) and BOC₂O (2.74 g, 12.5 mmol). After 18 h, the reaction mixture was concentrated, diluted with saturated aqueous NH₄Cl and extracted with EtOAc (2x). The combined organic extracts were washed with saturated aqueous NaHCO₃, brine, dried over MgSO₄, filtered, concentrated, and chromatographed to yield 2.60 g (62% over 2 steps) alcohol as an oil.

A solution of alcohol (2.60 g, 7.07 mmol) in THF (35 mL) at 0 °C was treated with carbon tetrabromide (4.64 g, 14.0 mmol) and triphenylphosphine (4.1 g, 15.6 mmol) and warmed to rt. After 30 min, the suspension was filtered through celite, concentrated and chromatographed to yield 2.76 g (91%) bromide as an oil.

A solution of bromide (300 mg, 700 mmol) in CH₃CN (7 mL) was treated with potassium carbonate (290 mg, 2.1 mmol) and dimethyl amine (2.0 M in THF, 2.8 mL, 5.6 mmol). The reaction mixture was heated to 70 °C in a sealed tube. After 5h, the

- 81 -

reaction mixture was cooled to rt, diluted with H₂O and extracted with CH₂Cl₂ (3x). The organic extracts were dried over MgSO₄, filtered and concentrated to provide the 250 mg (91%) amine as an oil.

5 A solution of carbamate (250 mg, 630 mmol) in CH₂Cl₂ (4 mL) was treated with trifluoroacetic acid (2.0 mL). After 5 h, the reaction mixture was concentrated. The residue was diluted with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂ (3x). The organic extracts were dried over MgSO₄, filtered and concentrated to yield 180 mg (97%) aniline as a solid.

10 A solution of aniline (77.0 mg, 0.262 mmol) in dichloroethane (2 mL) was treated with diisopropylethylamine (183 μ L, 1.05 mmol) and 3,5-dichloroisocyanate (99.0 mg, 0.520 mmol). After 6 h, the reaction mixture was diluted with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂ (3x). The organic extracts were dried over MgSO₄, filtered, concentrated and chromatographed to yield 66.6 mg (49%) of urea.

15 ¹H NMR (300 MHz, CDCl₃) δ 7.89 (s, 1 H), 7.84 (d, *J* = 6.6 Hz, 1 H), 7.69 (m, 1 H), 7.68 (d, *J* = 8.7 Hz, 2 H), 7.60 (t, *J* = 7.8 Hz, 1 H), 7.41 (d, *J* = 8.7 Hz, 2 H), 7.26 (s, 2 H), 6.97 (s, 1 H), 6.30 (s, 1 H), 3.78 (t, *J* = 7.2 Hz, 2 H), 2.33 (t, *J* = 7.2 Hz, 2 H), 2.24 (s, 6 H), 1.64 – 1.54 (m, 4 H)

HRMS (M+H⁺): 481.1544



20

EXAMPLES 223-229

Employing preparative procedures similar to those described in Example 222, the following compounds shown below in Table VI were prepared.

25

Table VI

Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃
223		564.1914	
224		548.3279	

- 82 -


225		582.2528	7.90 (s, 1 H), 7.86 (dt, $J = 8.1, 1.5, 1.2$ Hz, 1 H), 7.71 (d, $J = 8.4$ Hz, 2 H), 7.70 (m, 1 H), 7.61 (t, $J = 7.8$ Hz, 1 H), 7.55 (d, $J = 2.7$ Hz, 1 H), 7.53 (d, $J = 2.7$ Hz, 1 H), 7.49 – 7.42 (m, 2 H), 7.07 (t, $J = 9.3$ Hz, 1 H), 6.23 (s, 1 H), 6.22 (m, 1 H), 4.45 (m, 1 H), 3.81 (t, $J = 6.9$ Hz, 2 H), 2.87 (m, 1 H), 2.71 (d, $J = 9.9$ Hz, 1 H), 2.52 – 2.45 (m, 3 H), 2.30 – 2.20 (m, 2 H), 1.93 (s, 3 H), 1.65 – 1.50 (m, 5 H)	
226		465.1846		
227		477.1863		4 8 8 8 3 0
228		493.1564		4 8 8 8 3 2
229		511.2128		4 8 8 8 3 7

The following example illustrates the preparation of compounds using method

7.

5

EXAMPLE 230



To a stirred solution of 4-bromoaniline (9.4 g, 54.82 mmol) in 250 mL toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (16.11 g, 109.65 mmol), Pd(PPh₃)₄ (6.3 g, 5.48 mmol) and Na₂CO₃ (35 g, 330 mmol). The mixture was

- 83 -

degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed to yield 4.78 g (45%) of biaryl aniline.

5 A solution of biaryl aniline (2.50 g, 12.87 mmol) in CH₃CN (25 mL) was treated with potassium carbonate (2.67 g, 14.2 mmol) and ethyl 4-bromobutyrate (2.0 mL, 14.2 mmol) and heated to 80 °C. After 16 h, potassium carbonate (2.67 g, 14.2 mmol) and ethyl 4-bromobutyrate (2.0 mL, 14.2 mmol) were added. After 16 h further, the reaction mixture was cooled to rt, diluted with H₂O and extracted with EtOAc (2x). The organic extracts were dried over MgSO₄, filtered, concentrated and chromatographed to afford 2.10 g (<53%) of an inseparable mixture of monoalkylated along with
10 dialkylated aniline as an oil.

A solution of impure aniline (700 mg, <2.27 mmol) in dichloroethane (20 mL) was treated with diisopropylethylamine (870 µL, 5.00 mmol) and 3-chloro, 4-fluorophenyl isocyanate (566 µL, 4.50 mmol) and heated to 80 °C. After 36 h, the
15 reaction mixture was diluted with saturated aqueous NaHCO₃ and extracted with CH₂Cl₂ (3x). The organic extracts were dried over MgSO₄, filtered, concentrated and chromatographed to yield 740 mg (68%) of urea as a solid.

A solution of ester (740 mg, 1.54 mmol) in EtOH/THF (2:1, 12 mL) was treated with a solution of sodium hydroxide (1.0 N, 7 mL). After 1h, the reaction mixture was
20 concentrated, diluted with 1N sodium hydroxide and extracted with diethyl ether (2x). The aqueous phase was acidified to pH = 2 with 6 N HCl, and extracted with EtOAc (2x). The combined ethyl acetate layers were washed with water, dried over MgSO₄, filtered and concentrated to give 680 mg (97%) acid as a solid.

A solution of acid (100 mg, 0.221 mmol) in CH₂Cl₂ (2 mL) was treated with triethylamine (350 µL, 0.553 mmol), BOP reagent (117 mg, 0.265 mmol) and *N, N*-dimethylethylenediamine (36 µL, 0.33 mmol). After 24 h, the reaction mixture was
25 diluted with saturated aqueous NH₄Cl and extracted with EtOAc (2x). The combined organic extracts were washed with saturated aqueous NaHCO₃, brine, dried over MgSO₄, filtered, concentrated and chromatographed to yield 89.7 mg (71%) of amide.






30 ¹H NMR (300 MHz, CDCl₃) δ 7.86 (s, 1 H), 7.82 – 7.81 (m, 1 H), 7.68 – 7.58 (m, 5 H), 7.45 (d, *J* = 8.4 Hz, 2 H), 7.25 (m, 1 H), 7.02 (t, *J* = 8.7 Hz, 1 H), 6.62 (s, 1 H), 3.85 (t, *J* = 6.9 Hz, 2 H), 3.41 (q, *J* = 6.0 Hz, 2 H), 2.62 – 2.60 (m, 2 H), 2.34 (s, 6 H), 1.93 – 1.88 (m, 2 H)


- 84 -

HRMS (M+H⁺): 522.2065EXAMPLES 231-236

Employing preparative procedures similar to those described in Example 230,
 5 the following compounds shown below in Table VII were prepared.


Example VII

<u>Ex.</u>	<u>Structure/Name</u>	<u>HRMS</u>	<u>300MHZ-¹H NMR CDCl₃</u>
231		538.1766	
232		538.1784	
233		570.2429	
234		556.2328	
235		536.2339	

236		536.2339	
-----	---	----------	--

The following example illustrates the preparation of the compound using method 8.

5

EXAMPLE 237

To a stirred solution of 4-bromoaniline (9.4 g, 54.82 mmol) in 250 mL
 10 toluene:ethanol:H₂O (3:1:1) was added 3-cyanophenyl boronic acid (16.11 g, 109.65 mmol), Pd(PPh₃)₄ (6.3 g, 5.48 mmol) and Na₂CO₃ (35 g, 330 mmol). The mixture was degassed with N₂, then heated to 100 °C for 24 h. The reaction mixture was concentrated then diluted with EtOAc, washed with H₂O, dried over MgSO₄, filtered, concentrated and chromatographed to yield 4.78 g (45%) of biaryl aniline.

15 To a stirred solution of biaryl aniline (0.53 g, 2.73 mmol) and N-(tert-butoxycarbonyl)-L-prolinal (0.54 mL, 2.86 mmol) in methylene chloride (4mL) was added titanium isopropoxide (0.98 mL, 3.28 mmol) and stirred and rt for 24 h. The reaction mixture was cooled to 0°C and sodium cyanoborohydride (0.51 g, 8.19 mmol) was added in methanol (2 mL) drop-wise. The reaction was stirred 0°C for 20 mins
 20 and at rt for 5 h. The reaction mixture was diluted with EtOAc:water, 3:1, (12 mL) then filtered through Celite. The resulting filtrate was then washed with brine, dried over Na₂SO₄, concentrated and chromatographed to yield 0.656 g (64%) of amine.

To a stirred solution of amine (0.655 g, 1.737 mmol) and diisopropylethyl amine (1.51 mL, 8.687 mmol) in dichloroethane (3 mL) was added 4-fluoro-3-

- 86 -

trifluoromethylphenyl isocyanate (1.24 mL, 8.687 mmol) and stirred at 50°C for 24 h. The reaction mixture was cooled to rt then diluted with methylene chloride, washed with H₂O, aqueous NaOH, dried over Na₂SO₄, concentrated and chromatographed to yield 1.00 g (99%) of urea.

5 To a stirred solution of urea (1.00 g, 1.73 mmol) in methylene chloride (20 mL) was added trifluoroacetic acid (2.6 mL, 34.74 mmol) and stirred under N₂ at rt for 3 h. The reaction mixture was concentrated, then diluted with methylene chloride and washed with aqueous NaOH, dried and concentrated to yield 0.83 g (100%) of secondary amine.

10 To a stirred solution of amine (0.071 g, 0.147 mmol) in dichloroethane (1 mL) was added a 37% aqueous solution of formaldehyde (0.033 mL, 0.442 mmol), acetic acid (0.017 mL, 0.294 mmol), and sodium triacetoxyborohydride (0.063 g, 0.294 mmol) and stirred at rt for 24 h. The reaction mixture was quenched with aqueous NaOH and extracted with methylene chloride. The combined extracts were dried over Na₂SO₄, concentrated and chromatographed to yield 0.033 g (45%) amine.

¹H NMR (300 MHz, CDCl₃) δ 7.85-7.79 (m, 2H), 7.69-7.47 (m, 6H), 7.39 (d, J = 9.3 Hz, 2H), 7.10 (t, J = 10.6 Hz, 1H), 3.97-3.93 (m, 2H), 3.28-3.27 (m, 1H), 2.87 (m, 1H), 2.60 (s, 3H), 2.57-2.51 (m, 1H), 1.98-1.87 (m, 3H), 1.82-1.75 (m, 1H)

HRMS (M+H⁺): 497.1974


20

EXAMPLES 238-246







Employing preparative procedures similar to those described in Example 237, compounds were prepared whose structures are set forth in Table VIII as follows:

25



Table VIII

Ex.	Structure/Name	HRMS	300MHZ- ¹ H NMR CDCl ₃
238		479.1409	

- 87 -


239		465.1246	
240		479.1409	
241		449.1552	
242		463.1704	
243		483.1800	7.85-7.79 (m, 2H), 7.70-7.51 (m, 7H), 7.44 (d, $J = 9.3$ Hz, 2H), 7.09 (t, $J = 10.6$ Hz, 1H), 4.00-3.91 (m, 1H), 3.75-3.65 (m, 2H), 3.22-2.98 (m, 3H), 1.99-1.92 (m, 2H), 1.80-1.76 (m, 1H), 1.55-1.51 (m, 1H)
244		537.2287	

- 88 -

245		541.2239		
246		525.2278		

WHAT IS CLAIMED:

1. A compound of the formula:



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where

- 5 applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar¹ is an aryl or heteroaryl group,

Ar² is an aryl, heteroaryl or aralkyl group or Ar¹ and Ar² together form a
fluorene, substituted fluorene or fluorenone group with the proviso that Ar³ must be
10 arylene;

Ar³ is an arylene or heteroarylene group;


said Ar¹, Ar² and Ar³ groups possessing 0 to 3 substituents independently
selected from the group consisting of -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, halo, -CN, -(C₁-
C₆)alkoxy, -CF₃, -OCF₃, -CONH₂, -CONH(C₁-C₆)alkyl, -CON(C₁-C₆)alkyl (C₁-C₆)alkyl, -
15 NH₂, -NH C(O)(C₁-C₆)alkyl, -NHSO₂(C₁-C₆)alkyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -
SO₂(C₁-C₆)alkyl, methylenedioxy and NO₂;

X is O, S or N-CN;


Y is a single bond or a -(C₁-C₄)alkylene- group;

R¹ is thiazole, aryl or heteroaryl; or

20



- 90 -



5

,or

R¹ is -N(R⁵)₂, -NHC(O)(C₂-C₃)alkylene N(R⁵)₂; -C(O)NH(C₂-C₃)alkylene N(R⁵)₂; C(O)N(Me)(C₂-C₃)alkyleneN(R⁵)₂, -C(OH)(C₁-C₂)alkyleneN(R⁵)₂, -N(Me)(C₂-C₃)alkyleneN(R⁵)₂, -NH(C₂-C₃)alkyleneC(O)R⁵, -N(Me)(C₂-C₃)alkyleneN(Me)SO₂(R⁵) or -N(Me)(C₂-C₃)alkyleneC(O)N(R⁵)₂;

10

R² is H or -(C₁-C₆)alkyl.

R³ is independently H, or nonsubstituted or halosubstituted

15 -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₃-C₇)cycloalkyl(C₁-C₆)alkyl, -(C₁-C₆)alkoxy, -(C₁-C₆)alkoxy (C₁-C₆)alkylene, aryl, -aralkyl or -heteroaralkyl; or

- 91 -

R⁴ is H, nonsubstituted or halosubstituted -(C₁-C₆)alkyl, -NH(C₁-C₆)alkyl, -NHaryl, aryl; or alkoxy or hydroxy substituted alkyl, and

R⁵ is independently H, or nonsubstituted or halosubstituted -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkyl, -(C₃-C₇)cycloalkyl(C₁-C₆)alkyl, aryl, -aralkyl, -heteroaralkyl, -(C₁-C₆)alkoxy or (C₁-C₆)alkylene(C₁-C₆)alkoxy.


2. A compound as defined in Claim 1;

or a pharmaceutically acceptable addition salt and or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar¹ and Ar² are independently phenyl or pyridyl,

Ar³ is 1, 4-arylene,

R¹ is  in which R³ is -(C₁-C₆)alkyl, -(C₃-C₇)cycloalkylmethyl, (C₁-C₆)alkoxy- or (C₁-C₆)alkoxy(C₁-C₆)alkylene-,

R² is H,

X is O; and

Y is a single bond or -(C₁-C₃)alkylene.

3. A compound as defined in Claim 1

Or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar¹ and Ar² are independently phenyl or pyridyl,

Ar³ is 1,4-arylene,

- 92 -

R^1 is $-N(R^5)_2$ or $-C(O)NH(C_2-C_3)\text{alkylene}$ $N(R^5)_2$ in which each R^5 is independently H, $-(C_1-C_6)\text{alkyl}$, $-\text{ar}(C_1-C_6)\text{alkyl}$, heteroaryl, heteroarylalkyl, halo-substituted $-(C_1-C_6)\text{alkyl}$, $-(C_3-C_7)\text{cycloalkyl}$,

X is O; and

5 Y is $-(C_2-C_3)\text{alkylene}$.

4. A compound as defined in Claim 1


Or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

10 Ar^1 and Ar^2 are independently phenyl or pyridyl,

Ar^3 is 1,4-arylene,

R^1 is selected from



X is O; and

15 Y is $-(C_2-C_3)\text{alkylene}$.

5. A compound as defined in Claim 2

or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

20 Ar^1 is 3-substituted phenyl or pyridyl,

Ar^2 is halo-substituted or CF_3 -substituted phenyl or pyridyl and

R^3 is methyl, ethyl, propyl, $-\text{CH}_2\text{CH}_2\text{CF}_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.

- 93 -

6. A compound as defined in Claim 5 wherein the 3-substituent on the phenyl or pyridyl is –CN, –OCF₃ or chloro.


7 A compound as defined in Claim 3 wherein Ar¹ is 3-substituted phenyl or pyridyl, Ar² is halo-substituted or CF₃-substituted phenyl or pyridyl and R⁵ is methyl, ethyl, propyl, –CH₂CH₂CF₃, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.


8. A compound as defined in Claim 7 wherein the 3- substituent on the phenyl or pyridyl is –CN, –OCF₃ or chloro.


9. A compound as defined in Claim 4 wherein Ar¹ is 3-substituted phenyl or pyridyl, Ar² is halo-substituted or CF₃-substituted phenyl or pyridyl and R⁵ is methyl, ethyl, propyl, –CH₂CH₂CF₃, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.


10. A compound as defined in Claim 9 wherein the 3- substituent on the phenyl or pyridyl is –CN, –OCF₃ or chloro.


11. A compound as defined in Claim 1 selected from the group consisting of



















- 100 -



- 101 -



12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

5 13. A method of treating a metabolic disorder, eating disorder or diabetes in a subject in need thereof which comprises administering to said subject an effective amount of a compound as defined in claim 1.

14. A pharmaceutical composition which comprises an effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier thereof.

10 15 A method of treating eating disorders in a subject in need of such treatment which comprises administering to said subject a therapeutically effective amount of a compound of claim 1 or a pro-drug thereof or a pharmaceutically acceptable salt of said compound or of said pro-drug.

16. The method of claim 15 wherein said eating disorder is hyperphagia.

15 17. The method of claim 13 wherein said metabolic disorder is obesity.

18. A method of treating disorders associated with obesity in a subject in need of such treatment which comprises administering to said subject a therapeutically effective amount of a compound of claim 1 or a pro-drug thereof or a pharmaceutically acceptable salt of said compound or of said pro-drug.

20 19. The method of claim 18 wherein said disorders associated with obesity are type II diabetes, insulin resistance, hyperlipidemia and hypertension.

- 102 -

20. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

5 a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an antiobesity and/or anorectic agent such as a β_3 agonist, a thryomimetic agent, an anorectic agent or an NPY antagonist; and

a pharmaceutically acceptable carrier thereof.

10 21. A method of treating an eating disorder which comprises administering to a subject in need of such treatment

an amount of a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

15 a second compound, said second compound being an antiobesity and/or anorectic agent such as a β_3 agonist, a thryomimetic agent, an anorectic agent or an NPY antagonist;

wherein the amounts of the first and second compounds result in a therapeutic effect.

20

22. A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

25 a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a

- 103 -

protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosiglitazone, pioglitazone, or GW-1929, a sulfonylurea, glipazide, glyburide, or chlorpropamide; and a
5 pharmaceutically acceptable carrier therefor.

23. A pharmaceutical composition made by combining the compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

24. A process for making a pharmaceutical composition comprising combining a compound as defined in claim 1 and a pharmaceutically acceptable
10 carrier.

INTERNATIONAL SEARCH REPORT

PCT/US 01/45242

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D211/26 A61K31/4465 C07D211/58 C07D207/12 C07D207/14 C07D295/125 C07D241/04 C07C275/28 A61P3/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D C07C A61K A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 64394 A (STAMFORD ANDREW W ;DUGAR SUNDEEP (US); SCHERING CORP (US); WU YUSH) 16 December 1999 (1999-12-16) page 1-5	1-24
A	US 6 043 246 A (FUKURODA TAKAHIRO ET AL) 28 March 2000 (2000-03-28) cited in the application the whole document	1-24
A	US 5 908 830 A (CASCIERI MARGARET A ET AL) 1 June 1999 (1999-06-01) cited in the application column 6, line 1-20	1-24
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family		
Date of the actual completion of the international search 10 June 2002		Date of mailing of the international search report 17/06/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Lauro, P

INTERNATIONAL SEARCH REPORT

PCT/US 01/45242

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9964394	A	16-12-1999	AU 4317899 A	30-12-1999
			CN 1311773 T	05-09-2001
			EP 1086078 A1	28-03-2001
			WO 9964394 A1	16-12-1999
US 6043246	A	28-03-2000	AU 5135998 A	29-06-1998
			EP 0955293 A1	10-11-1999
			WO 9824768 A1	11-06-1998
US 5908830	A	01-06-1999	AU 723879 B2	07-09-2000
			AU 5160698 A	22-05-1998
			EP 0969852 A1	12-01-2000
			WO 9818481 A1	07-05-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.